Impact of intestinal helminth infection on HPV co-infection and the cervico-vaginal environment.
Project Number5K23AI168583-03
Contact PI/Project LeaderCLARK, EVA H
Awardee OrganizationBAYLOR COLLEGE OF MEDICINE
Description
Abstract Text
Project Summary
Dr. Clark is an Assistant Professor of Pediatric Tropical Medicine and Infectious Diseases at Baylor College of
Medicine (BCM) and a physician-scientist trained in immunoparasitology. Her career goal is to become an
independent molecular epidemiologist and perform high-quality clinical research that improves the health of
people living in low resource settings. The leading cause of cancer death for women in tropical low- and
middle-income countries (LMICs) is cervical cancer, which is caused by persistent infection with the human
papilloma virus (HPV). Cervical cancer rates are particularly high in LMICs with large intestinal helminth
burdens, and preliminary data show a significant population level association between intestinal helminth
infection and HPV infection. Dr. Clark proposes to evaluate whether intestinal helminth infection facilitates HPV
co-infection by altering the cervico-vaginal environment. She will conduct a cross-sectional study of adult
women undergoing cervical cancer screening in Peru. This innovative study aims to determine the prevalence
of HPV infection, evaluate cervico-vaginal cytokine profiles, and examine the distribution of cervico-vaginal
microbiota in women with and without intestinal helminth infection. Results of this work will suggest novel
interventions that are urgently needed to prevent cervical cancer in women living in LMICs. Dr. Clark’s unique
skill set will allow her to serve as a link between clinical discovery and public health system implementation of
new strategies for cervical cancer prevention. From a public health perspective, if intestinal helminth infection
increases a woman’s risk for HPV infection and therefore cervical cancer, deworming—a widely available, low-
cost intervention—should reduce the cervical cancer rates, thereby increasing the feasibility of cervical cancer
screening program implementation and reducing costs associated with early cervical dysplasia detection and
treatment programs. To accomplish these goals, Dr. Clark has developed a comprehensive career
development plan that combines thorough mentoring and training activities integrated into her clinical research
program. She will have regular meetings with her mentorship team, Dr. Elizabeth Chiao, an authority in virus
mediated malignancies and HPV screening, and Dr. Peter Hotez, a leader in parasitology and global health,
and will receive additional expert-level mentorship from her scientific advisory committee. Mentored research
will be supplemented with formal training activities including graduate-level coursework, directed studies, ad
participation in scientific meetings. Her career development plan is supported by a world-class scientific
environment at BCM, which offers ample opportunities for junior faculty development and provides all the
resources needed to achieve her career goals. The proposed mentored career development activities will
provide the focused mentorship and career development activities that Dr. Clark requires to succeed as an
independently funded molecular epidemiologist conducting high quality, high impact international research.
Public Health Relevance Statement
Project Narrative
Cervical cancer continues to cause disability and death in millions of women living in tropical regions of the
world who do not have access to cervical cancer screening and human papilloma virus (HPV) vaccination.
People living in tropical countries are commonly infected with intestinal worms (helminths), which can live
largely undetected in their hosts by muting the immune response. Understanding the impact of helminth
infection on the cervico-vaginal microenvironment may lead to the development of improved cervical cancer
prevention strategies in tropical countries.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AdultAdvisory CommitteesAffectBiologicalBiological AssayCancer EtiologyCervicalCervical Cancer ScreeningCervical dysplasiaCessation of lifeChildhoodChronicClinicalClinical ResearchCommunicable DiseasesCommunitiesCountryCross-Sectional StudiesDataDetectionDevelopmentDevelopment PlansEnvironmentEpidemiologistEpithelial CellsFundingGoalsHealthHealth systemHelminthsHelper-Inducer T-LymphocyteHigh Risk WomanHuman Papilloma Virus VaccinationHuman PapillomavirusHuman papilloma virus infectionImmuneImmune responseImmunityImmunization ProgramsImmunologicsInternationalInterventionIntestinesK-Series Research Career ProgramsLactobacillusLarge IntestineLinkMalignant NeoplasmsMalignant neoplasm of cervix uteriMediatingMedicineMentorsMentorshipMolecularParasitologyPathway interactionsPersonsPeruPhysiciansPopulationPrevalencePrevention strategyPublic HealthRegulatory T-LymphocyteResearchResource-limited settingResourcesRiskScientistSoilSpecimenStructureSwabT cell responseTeacher Professional DevelopmentTechnologyTestingTrainingTraining ActivityTropical MedicineUnited States National Institutes of HealthVaccinationVaginaVirusWhole-Genome Shotgun SequencingWomanWorkauthoritycancer riskcareercareer developmentcervical cancer preventioncervicovaginalcervicovaginal microbiomechronic infectionco-infectioncollegecostcytokinedisabilitydysbiosisfemale reproductive tractglobal healthhelminth infectionhigh riskimprovedinfection riskinnovationintervention costlow and middle-income countriesmeetingsmicrobiomemicrobiotanovelolder womenpolarized cellpreventprofessorprogramsscreeningscreening programskillstransmission processtreatment program
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
051113330
UEI
FXKMA43NTV21
Project Start Date
24-January-2022
Project End Date
31-December-2026
Budget Start Date
01-January-2024
Budget End Date
31-December-2024
Project Funding Information for 2024
Total Funding
$171,903
Direct Costs
$159,169
Indirect Costs
$12,734
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$171,903
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5K23AI168583-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5K23AI168583-03
Patents
No Patents information available for 5K23AI168583-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5K23AI168583-03
Clinical Studies
No Clinical Studies information available for 5K23AI168583-03
News and More
Related News Releases
No news release information available for 5K23AI168583-03
History
No Historical information available for 5K23AI168583-03
Similar Projects
No Similar Projects information available for 5K23AI168583-03